KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 103 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q3 2021. The put-call ratio across all filers is 1.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $224,785 | +23.2% | 12,941 | -0.1% | 0.00% | – |
Q2 2023 | $182,392 | +36.6% | 12,954 | +4.4% | 0.00% | – |
Q1 2023 | $133,553 | -28.2% | 12,412 | 0.0% | 0.00% | – |
Q4 2022 | $185,932 | +6.8% | 12,412 | -8.5% | 0.00% | – |
Q3 2022 | $174,162 | +29.2% | 13,564 | -2.5% | 0.00% | – |
Q2 2022 | $134,788 | -3.1% | 13,910 | -0.6% | 0.00% | – |
Q1 2022 | $139,140 | -30.1% | 13,998 | -17.3% | 0.00% | – |
Q4 2021 | $199,000 | -1.5% | 16,931 | -4.5% | 0.00% | – |
Q3 2021 | $202,000 | -22.0% | 17,725 | -4.8% | 0.00% | – |
Q2 2021 | $259,000 | -17.8% | 18,623 | +9.4% | 0.00% | – |
Q1 2021 | $315,000 | +5.0% | 17,016 | +0.4% | 0.00% | – |
Q4 2020 | $300,000 | +25.5% | 16,950 | +8.5% | 0.00% | – |
Q3 2020 | $239,000 | -24.6% | 15,621 | +27.9% | 0.00% | – |
Q2 2020 | $317,000 | +103.2% | 12,209 | +21.0% | 0.00% | – |
Q1 2020 | $156,000 | +69.6% | 10,088 | -4.1% | 0.00% | – |
Q3 2019 | $92,000 | -34.8% | 10,514 | +1.3% | 0.00% | – |
Q2 2019 | $141,000 | – | 10,381 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |